The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review.

ABSTRACT:

Background and objective

As the most common cancer to progress to brain metastases (BMs), lung cancer presents with intracranial involvement in approximately 20% of patients at the time of diagnosis and lung cancer BMs constitute approximately half of all BMs. The current clinical strategy for managing lung cancer BMs involves a combination of systemic anticancer therapies with local radiation or surgical interventions. The efficacy of systemic treatments is often constrained by the blood-brain barrier (BBB) and the poor inhibition effect of the drug itself. Despite these treatments, the median survival for patients with lung cancer BMs frequently does not exceed 2 years, underscoring the urgent need for novel and effective therapeutic approaches. Antibody-drug conjugate (ADC) cons

SUBMITTER: Zhou H 

PROVIDER: S-EPMC11736593 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature